Post-Hoc Analysis of RE-MEDY (TM) Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Schulman, Sam
  • Eriksson, Henry
  • Kakkar, Ajay
  • Kearon, Michael Clive
  • Schellong, Sebastian M
  • Mismetti, Patrick
  • Feuring, Martin
  • Hantel, Stefan
  • Kreuzer, Joerg
  • Goldhaber, Samuel Z

publication date

  • December 6, 2014

published in